Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
August 2, 2023 4:36 PM EDTAdaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of... More
Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
August 2, 2023 4:09 PM EDTAdaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of... More
